Key result
Levosimendan suggests superior outcomes compared to enoximone in cardiogenic shock.
Key points are not available for this paper at this time.
Comparison
Levosimendan vs enoximone
Design
Other
Answers are grounded in this paper and cite their sources.
May support levosimendan over enoximone in cardiogenic shock; hypothesis-generating and requires RCT confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Buerke et al. (2008) studied this question. Levosimendan is suggested to be superior to enoximone for the treatment of patients with cardiogenic shock.
Synapse has enriched 10 related papers. Consider them for comparative context: